|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Phase II clinical trial of docetaxel in refractory squamous cell carcinoma of the cervix:agynecologic oncology group study显示文摘 | Garcia A A Blessing J A Vaccarello L | 2007 | Am J Clin Oncol2007，30，4： | 1 |
| 2 | Pemetrexed and Cisplatin for the Treatment of advanced,persistent,or recurrent carcinoma of the cervix: a limitedaccess phase II trial of the gynecologic oncology group显示文摘 | Miller D S Blessing J A Ramondetta L M | 2014 | J Clin Oncol2014，32，25： | 1 |
| 3 | A phase II trial of dolastatin 10 in recurrent platinum sensitive ovarian carcinoma:A gynecologic on cology group study显示文摘 | Hoffman M A Blessing J A Lentz S S | 2003 | Gynecol Oncol2003，89，1： | 1 |
| 4 | Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: A Gynecologic Oncology Group study 显示文摘 | McGuire W P Blessing J A Bookman M A | 2000 | J Clin Oncol2000，18，5： | 1 |
| 5 | A phase Ⅱ evaluation of tirapazamine plus cisplatin in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer:A Gynecologic Oncology Group study显示文摘 | Covens A Blessing J Bender D | 2006 | Gynecol Oncol2006，100，3： | 1 |
| 6 | Phase Ⅲ study of cisplatin with or without paclitaxel in stage IVB,recurrent,or persistent squamous cell carcinoma of the cervix:a gynecologic oncology group study显示文摘 | Moore D H Blessing J A McQuellon R P | 2004 | J Clin Oncol2004，22，15： | 1 |
| 7 | Synergistic enhancement of chemokine generation and lung injury by C5a or the membrane attack complex of complement显示文摘 | CZERMAK B J LENTSCH A B BLESS N M | 1999 | American Journal of Pathology1999，154，5： | 1 |
| 8 | Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study显示文摘 | Rose P G Blessing J A Mayer A R | 1998 | J Clin Oncoi1998，16，2： | 1 |
| 9 | Phase Ⅱ trial of paclitaxel in patients with progressive ovarian carcinoma after platium-based chemotherapy: a gynecologic oncology group study显示文摘 | Thigpen J T Blessing J A Ball H | 2001 | J Chn Oncol2001，12，5： | 1 |
| 10 | Measuring the biodegradability of nonylphenol ether earboxylates, oetylphenol ether carboxylates, and nonylphenol 显示文摘 | Staples C A Williams J B Blessing R L | 1999 | Chemosphere1999，38，9： | 1 |
| 11 | Ifosfamide and doxombicin in the treatInent of advanced leiomyosarcomas of the utens: a gynecologic oncology group study显示文摘 | Sutton G Blessing J A Malfetano J H | 1996 | Gynecol Oncol1996，62，4： | 1 |
| 12 | Implicit learning of af- fective responses in dementia patients:a Face-Emotion-Associ ation paradigm显示文摘 | Blessing A Zoellig J Daromann G | 2010 | Aging Neuropsychol Cogn2010，17，6： | 1 |
| 13 | Phase Ⅱ evaluation of 9:aminocamptothecin (9-AC, NSC #603071) in platinum-resis tant ovarian and primary peritoneal carcinoma: a Gynecologic Oncology Group Study 显示文摘 | Miller D S Blessing J A Waggoner S | 2005 | Gynecol Oncol2005，96，1： | 1 |
| 14 | Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study 显示文摘 | DAVID H MOORE J A BLESSING R P | 2004 | J Clin Oncol2004，22，15： | 1 |
| 15 | A phase Ⅱ trial of dolastatin-10 in recurrent platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study显示文摘 | Hoffman M A Blessing J A Lentz S S | 2003 | Gynecol Oncol2003，89，1： | 1 |
| 16 | Paclitaxel, an active agent in nonsquamous carcinomas of the uterine cervix: a gynecologic oncology group study 显示文摘 | Curtin J P Blessing J A Webster K D | 2001 | J Clin Oncol2001，19，5： | 1 |
| 17 | NF-kappaB Activation during IgG Immune Complex-induced Lung Injury: Requirements for TNF-alpha and IL-1beta but Not Complement 显示文摘 | Lentsch A B Czermak B J Bless N M | 1998 | Am J Pathol1998，152，： | 1 |
| 18 | Computational modeling of the penetration response of a high-purity ceramic显示文摘 | Simha C H M Bless S J Bedford A | 2002 | International Journal of Impact Engineering2002，，27： | 1 |
| 19 | A phase II evaluation of trabectedin in the treatment of advanced, persistent, or recurrent uterine leiomyosarcoma: a gynecologic oncology group study显示文摘 | Monk B J Blessing J A Street D G | 2012 | Gynecolc Oncol2012，124，1： | 1 |
| 20 | Evaluation of pemetrexed ( Alimta,LY 231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix : a phase Ⅱ study of the Gynecologic Oncology Group显示文摘 | Miller D S Blessing J A Bodurka D C | 2008 | Gynecol Oncol2008，110，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员